NASDAQ
SRRK

Scholar Rock Holding Corp

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Scholar Rock Holding Corp Stock Price

Vitals

Today's Low:
$6.09
Today's High:
$6.38
Open Price:
$6.09
52W Low:
$5.56
52W High:
$13
Prev. Close:
$6.16
Volume:
134248

Company Statistics

Market Cap.:
$353.70 million
Book Value:
3.671
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$-89851000
Profit Margin:
0%
Return on Assets TTM:
-28.56%
Return on Equity TTM:
-60.1%

Company Profile

Scholar Rock Holding Corp had its IPO on 2018-05-24 under the ticker symbol SRRK.

The company operates in the Healthcare sector and Biotechnology industry. Scholar Rock Holding Corp has a staff strength of 114 employees.

Stock update

Shares of Scholar Rock Holding Corp opened at $6.09 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $6.09 - $6.38, and closed at $6.2.

This is a +0.65% increase from the previous day's closing price.

A total volume of 134,248 shares were traded at the close of the day’s session.

In the last one week, shares of Scholar Rock Holding Corp have slipped by -1.43%.

Scholar Rock Holding Corp's Key Ratios

Scholar Rock Holding Corp has a market cap of $353.70 million, indicating a price to book ratio of 1.5203 and a price to sales ratio of 11.3337.

In the last 12-months Scholar Rock Holding Corp’s revenue was $0 with a gross profit of $-89851000 and an EBITDA of $-159024000. The EBITDA ratio measures Scholar Rock Holding Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Scholar Rock Holding Corp’s operating margin was 0% while its return on assets stood at -28.56% with a return of equity of -60.1%.

In Q2, Scholar Rock Holding Corp’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.

Scholar Rock Holding Corp’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-1.93 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Scholar Rock Holding Corp’s profitability.

Scholar Rock Holding Corp stock is trading at a EV to sales ratio of 4.6821 and a EV to EBITDA ratio of -1.3802. Its price to sales ratio in the trailing 12-months stood at 11.3337.

Scholar Rock Holding Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$284.90 million
Total Liabilities
$24.27 million
Operating Cash Flow
$-15241000.00
Capital Expenditure
$41000
Dividend Payout Ratio
0%

Scholar Rock Holding Corp ended 2024 with $284.90 million in total assets and $0 in total liabilities. Its intangible assets were valued at $284.90 million while shareholder equity stood at $202.50 million.

Scholar Rock Holding Corp ended 2024 with $0 in deferred long-term liabilities, $24.27 million in other current liabilities, 55000.00 in common stock, $-587936000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $108.06 million and cash and short-term investments were $248.73 million. The company’s total short-term debt was $7,280,000 while long-term debt stood at $49.90 million.

Scholar Rock Holding Corp’s total current assets stands at $259.81 million while long-term investments were $0 and short-term investments were $140.67 million. Its net receivables were $0 compared to accounts payable of $3.04 million and inventory worth $0.

In 2024, Scholar Rock Holding Corp's operating cash flow was $-15241000.00 while its capital expenditure stood at $41000.

Comparatively, Scholar Rock Holding Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$6.2
52-Week High
$13
52-Week Low
$5.56
Analyst Target Price
$22

Scholar Rock Holding Corp stock is currently trading at $6.2 per share. It touched a 52-week high of $13 and a 52-week low of $13. Analysts tracking the stock have a 12-month average target price of $22.

Its 50-day moving average was $6.74 and 200-day moving average was $8.2 The short ratio stood at 15.64 indicating a short percent outstanding of 0%.

Around 208.1% of the company’s stock are held by insiders while 9866.2% are held by institutions.

Frequently Asked Questions About Scholar Rock Holding Corp

The stock symbol (also called stock or share ticker) of Scholar Rock Holding Corp is SRRK

The IPO of Scholar Rock Holding Corp took place on 2018-05-24

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$0.18
-0.03
-13.27%
$0.54
-0.01
-1.82%
$10.17
0
-4.82%
$8.41
0.23
+2.81%
$1.56
-0.12
-7.14%
$0.76
-0.02
-2.82%
$53.5
0
0%
$4.45
-0.19
-4.09%
$0.66
-0.02
-2.96%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and iron-restricted anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Address

301 Binney Street, Cambridge, MA, United States, 02142